FROM THE EDITOR
The analysis in this article is based on FDA’s September 18, 2026 warning letter to Empower Pharmacy, Empower’s public statements, and publicly available information about the surrounding enforcement environment. Empower has not yet responded publicly to the warning letter’s substantive allegations, and the company’s response — when it comes — may contest or clarify the agency’s characterization of its operations. This article analyzes what the warning letter says and what its legal theory means for the GC community. It does not establish that the allegations are accurate.
With that sourcing note stated, the article.
On September 18, 2026, FDA issued a warning letter to Empower Pharmacy — the company’s third. The letter was addressed to the company’s CEO by name. It contained a phrase that had never appeared in an FDA compounding enforcement document before: “pretextual compounding.”
That phrase is the article.
FDA did not borrow “pretextual compounding” from its own regulatory vocabulary. It appears to have drawn the phrase from arguments that Eli Lilly and Novo Nordisk had been making in federal court against 503A compounders who were manufacturing products that copied approved GLP-1 drugs in large quantities. FDA looked at what the private plaintiffs were arguing, concluded it described the conduct the agency was concerned about, and put the phrase in a regulatory enforcement document.
When the regulator starts borrowing the plaintiff’s bar’s language and putting it in warning letters, something has changed in the enforcement posture. This article explains what changed, what the warning letter actually says, and what it means for any company that sells to, buys from, or operates in the 503A/503B compounding space.
John LaRocca
THE ENFORCEMENT THREAD
Empower Pharmacy is a Houston-based 503A compounding pharmacy — one of the country’s largest. A 503A pharmacy compounds medications for individual patients pursuant to a prescription, as opposed to a 503B outsourcing facility, which can compound in larger quantities without patient-specific prescriptions.
The FDA warning letter of September 18, 2026 is the company’s third. The first and second letters addressed sterility and manufacturing practice concerns following prior inspections. The September 18 letter — which FDA issued following a November 2025 inspection of Empower’s Houston facility — escalates significantly. It addresses not just manufacturing deficiencies but the legal theory under which FDA contends Empower’s entire GLP-1 compounding program is operating.
That distinction matters. A warning letter addressing manufacturing practices is a compliance remediation problem. A warning letter challenging the legal basis for a compounding program raises a different question: FDA is asserting that the activity itself — not just how the activity is being conducted — may fall outside the statutory exemption that permits it. Whether that assertion is correct is a question the company’s response and, potentially, subsequent proceedings will address.
The broader context: FDA’s shortage-based authorization for GLP-1 compounding under the Federal Food, Drug, and Cosmetic Act was tied to semaglutide and tirzepatide appearing on the Drug Shortage list. FDA removed semaglutide from the shortage list earlier in 2026 and has indicated that the tirzepatide shortage designation is under review. As that authorization narrows, FDA’s enforcement posture has hardened across the 503A compounding sector generally. This letter is one data point in that broader pattern.
THE PRETEXTUAL COMPOUNDING STANDARD
Section 503A of the Federal Food, Drug, and Cosmetic Act permits a licensed pharmacist or physician to compound a drug for an identified individual patient pursuant to a prescription. 503A compounded drugs are exempt from the Act’s new drug approval requirements, the requirement for adequate directions for use, and FDA’s current good manufacturing practice regulations — a significant regulatory carve-out.
That carve-out is conditioned on several requirements, two of which are central to the September 18 letter.
First, a 503A pharmacy cannot compound drugs “regularly or in inordinate amounts” that are essentially copies of commercially available drug products. Second, when a drug copies an approved product, the prescribing practitioner must provide a statement that the commercially available product does not meet the patient’s needs — a “significant difference” determination — and the compounded product must be clinically different in a meaningful way.
According to the warning letter, FDA’s position is that Empower’s GLP-1 compounding program fails on both counts. On the “regularly or in inordinate amounts” prohibition, the letter points to production volumes that FDA characterizes as inconsistent with patient-specific prescription compounding for identified individual patients. On the significant-difference requirement, the letter identifies two specific alleged failures: prescribers using identical pre-generated significant-difference statements (which FDA interprets as suggesting the statements are platform-generated rather than individually authored), and significant-difference determinations that FDA contends do not identify a specific patient need that the commercially available product cannot meet.
The word “pretextual” appears in FDA’s characterization of the conduct the agency believes it is seeing: the regulatory exempt pathway, FDA contends, is being used as a pretext for large-scale manufacturing of products that copy commercially available approved drugs, rather than as a genuine patient-specific compounding operation. The 503A exemption was designed to permit individual patient care; FDA’s theory is that using it as a gateway to scale pharmaceutical manufacturing falls outside what Congress intended the exemption to cover.
That framing is new in FDA enforcement documents. FDA has challenged specific compounding practices for years. What it had not previously done was characterize a compounding program as pretextual at the theory level — asserting that the structural premise of the program’s claim to the 503A exemption is defective. Whether that theory holds up, and whether Empower’s response demonstrates that the facts have been characterized inaccurately, are open questions.
WHERE THE LANGUAGE CAME FROM
The phrase “pretextual compounding” does not appear to have originated at FDA. It appears in federal court filings.
Eli Lilly and Novo Nordisk each filed litigation against 503A compounders selling products that copied their GLP-1 therapies. Among the arguments those plaintiffs made: the compounders’ 503A claims were pretextual because no pharmacist was actually compounding individualized medications for specific patients. The 503A exemption requires patient-specific prescriptions and individual patient care; the plaintiffs’ argument was that large-scale manufacturing using the exemption as a shield was not what the statute was designed to permit.
FDA’s warning letter uses similar framing. Whether the agency deliberately adopted private plaintiffs’ language, independently arrived at the same characterization, or the convergence is coincidental is not established by the document itself. What is clear is that the phrase now appears in a regulatory enforcement document, and that its meaning in that context — an agency allegation that a statutory exemption is being misused — carries enforcement consequences different from those of a private lawsuit.
For GC practice, the mechanism is worth noting regardless of how the Empower matter ultimately resolves. Private litigation against a regulated company or industry generates legal theories that the regulator may read and, in some cases, adopt. When sophisticated private plaintiffs develop arguments that challenge a practice the regulator also views skeptically, the regulator’s subsequent enforcement documents sometimes reflect those arguments. The Lilly and Novo suits produced a partial dismissal in 2026 — some claims survived, others did not — and the outcome of those suits does not determine the enforceability of FDA’s warning letter theory. But the convergence between private litigation theory and agency enforcement framing is a pattern that GCs in regulated industries should track.
THE CEO LIABILITY DIMENSION
The September 18 warning letter was addressed to Arta Shaun Noorian, CEO of Empower Pharmacy, by name and title.
FDA warning letters are typically addressed to the company. When they are addressed to an individual officer by name, the agency is signaling something about personal exposure — that the identified person may face individual accountability for the violations described, separate from the company’s liability.
The legal basis for personal liability in FDA enforcement derives from United States v. Park, 421 U.S. 658 (1975). Under the Park doctrine, a corporate officer who has the authority and responsibility to prevent or correct a violation of the Act can be held criminally liable for the violation — without proof that the officer had actual knowledge of the violation or acted with criminal intent. The standard is position and responsibility, not knowledge or intent.
The Park doctrine has been a background feature of FDA enforcement for decades. Its direct application is most common in criminal prosecutions. A warning letter addressed to a CEO by name puts the officer on notice that FDA is tracking personal responsibility — that if the violations are not corrected, and if FDA pursues criminal enforcement, the CEO’s individual exposure is on the table. This is true regardless of whether the company ultimately contests and prevails on the underlying violations; the signal the naming convention sends is about the agency’s framing of accountability at the time the letter is issued.
For any GC whose company is in a regulated industry subject to FDA jurisdiction, the personal CEO liability dimension of this letter carries a structural lesson. The GC who creates a compliance infrastructure in which the CEO is informed about material FDA regulatory risks when they are identified — not after the warning letter arrives — serves two purposes: it is genuinely better governance, and it creates a record demonstrating that when violations occurred, the officer acted responsibly within the limits of what was known. That record is the most available defense against Park liability.
THE 503A SIGNIFICANT-DIFFERENCE REQUIREMENT — WHAT FDA’S ALLEGATIONS TARGET
The significant-difference determination is the compounding pharmacy’s most legally consequential document under 503A when the product copies a commercially available drug. It is also, based on the Empower warning letter, the element FDA contends is inadequate in high-volume compounding operations.
Under FDA’s reading of 503A, when a compounding pharmacy compounds a drug that is essentially a copy of a commercially available approved product, the prescribing practitioner must attest that the commercially available product does not meet the specific patient’s needs. FDA’s allegations in the Empower letter focus on three compliance failures it contends it observed:
Pre-generated statements. FDA alleges that identical significant-difference statements appeared across multiple prescriptions — which FDA interprets as inconsistent with genuine individualized clinical determinations. Whether the company’s response will demonstrate that the statements reflected common clinical scenarios rather than automated generation remains to be seen.
Inadequate clinical grounding. FDA contends that statements in the record did not identify specific patient needs that the commercially available product could not meet. This is a factual allegation that the company’s clinical documentation may address.
Third-party platform generation. FDA’s letter raises the concern that significant-difference statements may have been produced by third-party platforms rather than authored by prescribers. This is an allegation about process; the company’s response may contest it or provide context that FDA did not have at inspection.
The compliance lesson for any GC reviewing 503A operations is straightforward regardless of how Empower’s matter resolves: the significant-difference determination protocol — who generates it, how it is documented, whether prescriber attestations are individualized and clinically specific — is where FDA’s enforcement attention is concentrating. A compliance audit of that protocol is warranted in any high-volume 503A operation.
WHERE THE THREAD STANDS NOW
Two developments after the September 18 warning letter extend the enforcement pattern:
Apothecary Pharma Class II recall (October 8, 2026). FDA and Apothecary Pharma announced a Class II recall of 22 lots of compounded tirzepatide products. A Class II recall involves products that may cause temporary or reversible adverse health consequences. The Apothecary recall is unrelated to Empower’s warning letter — Apothecary is a different 503A pharmacy — but it occurred within weeks of FDA’s Empower action. Whatever the individual facts of each situation, the enforcement environment around compounded GLP-1s is not a single-company story.
FDA patient advisory (October 2026). FDA issued a public advisory warning patients against using compounded GLP-1 products, citing risks associated with dosing accuracy, sterility, and product identity. The advisory is directed at patients, not companies, but its content reflects FDA’s stated regulatory position: compounded GLP-1 products carry risks that commercially approved products do not.
The September 18 warning letter, the Apothecary recall, and the FDA patient advisory form a three-point pattern at the sector level: a major enforcement action against a large 503A compounder, a safety recall from a different 503A compounder, and a public advisory warning patients away from compounded GLP-1s generally. Whether that pattern reflects coordinated enforcement strategy or convergent individual actions, the GC of any company with 503A exposure should be tracking it.
WHAT THE GC NEEDS TO UNDERSTAND
The Empower warning letter and the surrounding enforcement pattern have implications beyond the compounding pharmacy sector. Three categories of companies need GC-level attention to this development.
Companies that supply 503A compounders. API suppliers, equipment vendors, testing labs, and distribution partners who serve 503A compounding pharmacies should understand the scope of those relationships and the FDA exposure that could accompany them if the enforcement ramp reaches criminal prosecution. The supply relationship is not automatically a shield against individual exposure.
Healthcare systems and prescription platforms that channel prescriptions to 503A compounders. The significant-difference documentation allegation in the Empower letter — specifically, the use of pre-generated statements from third-party platforms — points at the prescription-generation infrastructure that high-volume compounding operations use. If a telemedicine platform or prescription management system generates the significant-difference statements attached to compounding prescriptions, that platform’s own compliance exposure in a hardening enforcement environment is a question its GC should be examining.
Any regulated company watching FDA’s enforcement doctrine develop. The pretextual compounding theory is, at the level of regulatory doctrine, an assertion that a statutory exemption has limits — that a company cannot use an exemption as a business model if the underlying activity is not what the exemption was designed to permit. That doctrinal move is not unique to compounding. Regulated companies in any sector operating under statutory exemptions should review their compliance posture against the question FDA is implicitly asking: is the use of this exemption genuinely consistent with its purpose? Whether or not the theory succeeds against Empower, it is now in an FDA enforcement document, and the GC community needs to understand it.
WORKSTREAM 1 — IMMEDIATE: Audit Your 503A Exposure Map
If your company has any relationship with the 503A compounding sector — as a supplier, a customer, a distribution partner, or a prescription-channeling platform — the first legal task is an exposure map. Who are your compounding counterparties? What products do you supply to them or receive from them? What volume of those products involves commercially available approved drugs? What does your contractual allocation of FDA compliance obligations look like?
This is a defensive audit, not a remediation project. The point is not to terminate relationships with compounding pharmacies. The point is to understand, before FDA’s enforcement actions reach your counterparties, what the exposure profile is and what your disclosure and response framework looks like.
BUSINESS IMPACT: Companies that understand their 503A exposure map before a warning letter arrives at a counterparty are in a materially better position than companies that discover their exposure when the enforcement news breaks. The difference is preparation time — and preparation time is the most valuable resource in a regulatory enforcement sequence.
WORKSTREAM 2 — NEAR-TERM: Map the Personal Liability Doctrine for Your CEO and C-Suite
The Park doctrine is not new law. Every GC in a regulated industry should already have a working knowledge of it. But the Empower letter’s direct CEO naming is a reminder that the doctrine is live and that FDA is willing to invoke it in enforcement documents.
The near-term workstream is a review of your compliance information flow: when the CEO and other C-suite officers are informed about material regulatory risks, in what form, and what documentation exists of that information flow. The GC who can demonstrate that the CEO was informed about a compliance risk, received a remediation recommendation, and responded appropriately has built a factual record that is the best available defense against Park liability. The GC who cannot demonstrate that information flow has not built that record.
This is a compliance governance review: does your company’s regulatory reporting structure ensure that the right people know about the right risks at the right time, and does your documentation infrastructure support that?
BUSINESS IMPACT: The personal liability dimension of FDA enforcement is the dimension most likely to generate board-level concern and executive-level attention to compliance investment. The GC who uses the Empower letter to open a structured conversation about C-suite regulatory reporting is using an external event to advance an internal governance improvement that benefits the company regardless of whether FDA enforcement ever reaches it.
WORKSTREAM 3 — STRATEGIC: Track the Regulatory Doctrine Adoption Pipeline
The pretextual compounding story is a specific instance of a regulatory phenomenon worth tracking: enforcement doctrine that originates in private litigation and later appears in agency enforcement documents. The Lilly/Novo litigation theories and FDA’s warning letter language converge around the same characterization. The migration of analytical framing from courtroom to agency enforcement document — whatever its precise mechanism — happened faster than most companies in the 503A space anticipated.
The strategic workstream is a systematic approach to monitoring private litigation against your industry — not just as legal risk in its own right, but as a potential leading indicator of regulatory enforcement framing. Private plaintiffs with sophisticated legal teams develop theories about conduct they believe is unlawful. Those theories, when they resonate with the regulatory record the agency has independently compiled, sometimes appear later in agency enforcement documents.
For the compounding sector specifically: the Lilly and Novo suits continue. There are additional defendants, additional claims, and additional briefing cycles ahead. Each brief is a potential data point. The GC of any company with 503A exposure should be tracking those filings with that lens in mind.
BUSINESS IMPACT: Regulatory doctrine that migrates from private litigation typically provides a window — months, sometimes longer — between its articulation in court filings and its appearance in agency enforcement documents. That window is compliance review time. The GC who uses it is addressing risk before enforcement. The GC who misses it is addressing risk after enforcement — which is a different problem with much lower leverage.
PULL QUOTE: “A warning letter challenging the legal basis for a compounding program raises a different question than one addressing manufacturing deficiencies. FDA is asserting that the structural premise of the 503A claim may be defective. Whether that assertion holds up is an open question — but the theory is now in an FDA enforcement document.”
COMING NEXT
Baxter International received a management oversight letter from FDA in the aftermath of the Hurricane Helene supply disruption — a letter that raises questions about the scope of FDA’s authority to require management accountability for supply chain resilience, not just for product quality. What the letter says, what it doesn’t say, and what it means for every pharmaceutical company whose supply chain runs through a single critical manufacturing site. Issue #14.
ABOUT THE AUTHOR
John LaRocca is the founder of LaRocca Advisory Services and the author of The GC Playbook. He served as CLO at Aerie Pharmaceuticals (Aerie/Alcon, ~$930M), Y-mAbs Therapeutics (SERB, $412M), and Eagle Pharmaceuticals, with 37 years of legal experience and 26 years at the GC/CLO level in specialty pharma and biotech. The GC Playbook is published on Substack at laroccaj.substack.com.
© 2026 LaRocca Advisory Services | laroccaj.substack.com


